Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved dose adjusted rituximab in combination with etoposide, prednisolone, doxorubicin, cyclophosphamide and vincristine (DA-R EPOCH) therapy for reimbursement as a treatment option for the treatment of patients with CD20 positive diffuse large B-cell Non Hodgkins Lymphoma (NHL).
This is written in the approval document as:
Treatment of patients with CD20 positive diffuse large B-cell Non Hodgkins lymphoma (NHL).
Citation
Dose Adjusted riTUXimab, Etoposide, prednisoLONE, DOXOrubicin, cycloPHOSphamide and vinCRIStine (DA-R EPOCH) Therapy, 2023, version number 4, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/355-dose-adjusted-r-epoch-therapy.pdfTherapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | CD20 + | Diffuse Large B-Cell Lymphoma | Cyclophosphamide, Doxorubicin, Etoposide, Prednisolone, Rituximab, Vincristine | |
| Sensitivity (+) | CD20 + | Non-Hodgkin Lymphoma | Cyclophosphamide, Doxorubicin, Etoposide, Prednisolone, Rituximab, Vincristine |